Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

The last time I wrote about Replimune Group, Inc. (REPL) it was in a Seeking Alpha article entitled "Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch." With respect to this ...